Leqvio Cost in New York 2026: Inclisiran Price, Insurance, and Coverage Guide

What Is Inclisiran and Why Does the Price Matter?

Inclisiran (brand name Leqvio) is a small interfering RNA (siRNA) therapy that silences the gene encoding PCSK9 in liver cells, which keeps LDL receptors active longer and pulls LDL-cholesterol out of circulation. The FDA approved it on December 22, 2021, for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering on top of maximally tolerated statins. [1]

Cost matters here for a specific structural reason. Unlike a daily oral pill, inclisiran is administered only twice a year after two loading doses, meaning each injection event carries a large per-visit price tag. A single 284 mg prefilled syringe lists at approximately $3,240 at wholesale acquisition cost (WAC). Spread across 12 months with two injections per year in the maintenance phase, that works out to the $540/month figure Novartis cites. Most patients do not pay list price, but understanding that baseline number is necessary before evaluating what New York insurance tiers, copay programs, and compounding options actually save.

The key trials established why clinicians pursue this drug despite the cost. In ORION-10 (N=1,561, U.S.-only population), inclisiran 284 mg produced a 52.3% placebo-corrected reduction in LDL-C from baseline at day 510 (P<0.001). [2] ORION-11 (N=1,617, European and South African population) showed a 49.9% placebo-corrected LDL-C reduction at the same timepoint (P<0.001). [2] These reductions were sustained across the 17-month follow-up period, a durability profile that separates inclisiran from agents requiring daily or biweekly dosing.

The American College of Cardiology and American Heart Association 2022 Guideline on Cardiovascular Risk Reduction states: "For patients with clinical ASCVD who are on maximally tolerated statin therapy and have LDL-C levels persistently 70 mg/dL or higher, PCSK9 inhibition is recommended." [3] Inclisiran's siRNA mechanism fits within this class recommendation.

Leqvio List Price vs. Real-World Cost in New York in 2026

The Novartis WAC for one inclisiran 284 mg injection is approximately $3,240. Two injections per year in the maintenance phase produces a WAC-based annual cost of ~$6,480, or $540/month when annualized. New York retail pharmacy average cash-pay price tracks closely to this WAC figure in 2026 because inclisiran is not yet subject to the same generic competition or broad rebating dynamics that compress prices on older cardiovascular drugs.

A 2023 cost-effectiveness analysis published in JAMA Cardiology estimated inclisiran's incremental cost-effectiveness ratio at approximately $503,000 per quality-adjusted life year (QALY) at WAC in a U.S. secondary-prevention population, concluding that meaningful price reductions would be required to meet conventional $100,000, $150,000 per QALY thresholds. [4] That analysis used a 40-year time horizon and assumed 50% LDL-C reduction sustained from ORION-10 and ORION-11 data.

For New York patients specifically, three price points are relevant:

WAC / uninsured cash price. Approximately $3,240 per injection, $6,480 per year, or $540/month annualized. This is the worst-case scenario for a patient with no coverage and no access to the Novartis program.

Commercially insured with Novartis Leqvio Copay Card. Eligible patients pay $0 per dose. The card covers up to the full cost of the drug for patients with commercial insurance. Government-insured patients (Medicare, Medicaid) are not eligible for this card under federal anti-kickback statute carve-outs.

New York Medicaid. Covered with prior authorization. Details are in the section below.

New York Medicaid Coverage for Leqvio

New York Medicaid includes inclisiran on its preferred drug list with a prior authorization requirement. The PA process requires documentation of two conditions: a qualifying diagnosis (established ASCVD or HeFH confirmed by genetic testing or clinical criteria) and an inadequate LDL-C response (typically LDL-C remaining at or above 70 mg/dL) despite maximally tolerated statin therapy, with or without ezetimibe. [5]

Prescribers submit PA requests through the New York eMedNY system. Typical processing takes 3 to 5 business days for standard requests. Urgent medical necessity requests can be processed within 24 hours. If the PA is denied, the patient or prescriber may request a fair hearing through the New York State Department of Health Office of Administrative Hearings.

New York Medicaid Managed Care plans administered through carriers such as Fidelis Care, MetroPlusHealth, and Healthfirst each implement the state formulary requirements but may add their own step-therapy protocols. Specifically, some managed care plans require a 90-day documented trial of a PCSK9 monoclonal antibody (alirocumab or evolocumab) before approving inclisiran, citing the longer post-market data history for those agents. Checking the specific plan formulary before prescribing is advisable.

For patients enrolled in the Medicare Prescription Drug Plan (Part D), inclisiran coverage varies by plan. A 2024 analysis from the Kaiser Family Foundation found that 61% of standalone Part D plans covered at least one PCSK9 inhibitor, but inclisiran specifically appeared on fewer formularies than evolocumab or alirocumab due to its higher WAC and limited rebate agreements at the time of that analysis. [6] NY-based Medicare Advantage plans covering inclisiran generally place it on Tier 4 or Tier 5, with annual out-of-pocket costs potentially reaching the $2,000 Medicare Part D cap introduced under the Inflation Reduction Act for 2025 and beyond.

Commercial Insurance Coverage for Leqvio in New York

Major commercial carriers operating in New York cover inclisiran under varying tier placements. Empire BlueCross BlueShield, UnitedHealthcare of New York, Aetna, and Cigna all list inclisiran on their specialty formularies as of early 2026, typically on Tier 4 or Tier 5 with prior authorization and, in some cases, step therapy through a generic statin and ezetimibe first.

The Novartis Leqvio Copay Assistance Program reduces out-of-pocket cost to $0 for commercially insured patients who meet eligibility criteria. Enrollment is completed online at the Novartis patient services portal or through a HealthRX-affiliated prescriber. The card has no income cap for commercially insured patients, which distinguishes it from some manufacturer programs that apply household income limits. [7]

For large employer-sponsored plans in New York, inclisiran is occasionally carved out to a specialty pharmacy benefit manager rather than the standard pharmacy benefit. In those cases, the drug is dispensed through a specialty pharmacy (such as Accredo or CVS Specialty) and administered in-office or in an infusion center, with billing routed through the medical benefit rather than the pharmacy benefit. Patients should confirm whether their plan uses medical-benefit or pharmacy-benefit billing, as the cost-sharing structure differs significantly.

A patient whose plan uses medical-benefit billing may face a coinsurance of 10 to 20% of the allowed amount after deductible, which on a $3,240 injection could still reach several hundred dollars per dose. In that scenario, the Novartis copay card typically covers the remaining patient liability, but the card's annual cap (currently $13,000 per calendar year per the Novartis program terms) should be confirmed at enrollment.

Is Compounded Inclisiran Legal in New York?

Compounded inclisiran is legal in New York through licensed 503A compounding pharmacies, subject to strict oversight from the New York State Board of Pharmacy and the requirements of Section 503A of the Federal Food, Drug, and Cosmetic Act. [8]

503A pharmacies compound for individual patients based on a valid patient-specific prescription from a licensed prescriber. They may not produce inclisiran in large batches for office stock or general sale. The FDA's guidance on compounding of drugs that are essentially copies of commercially available products applies here. Because Leqvio is FDA-approved and commercially available, a 503A pharmacy compounding inclisiran must meet the "not essentially a copy" standard, which generally requires the prescriber to document a clinical difference (for example, a patient allergy to an excipient in the branded product or a need for a different concentration or delivery form). [9]

The cost profile for compounded inclisiran from a New York 503A pharmacy is substantially lower than the Novartis branded product. Some pharmacies list compounded inclisiran at minimal or no direct cost to the patient when billed under specific arrangements, though cash pricing at most 503A pharmacies in 2026 runs considerably below the $3,240 WAC. Pricing varies significantly by pharmacy and patient circumstances.

503B outsourcing facilities, which can compound in bulk without patient-specific prescriptions, cannot legally compound inclisiran while the branded product remains commercially available and is not on the FDA's drug shortage list. As of January 2026, Leqvio is not on the FDA drug shortage list. [10] Any 503B facility offering bulk compounded inclisiran in New York would be operating outside federal law.

Prescribers in New York considering compounded inclisiran should document the clinical rationale in the patient record, confirm the compounding pharmacy's current 503A registration with the New York State Board of Pharmacy, and verify the pharmacy's USP 797 sterile compounding compliance, since inclisiran is an injectable product.

HealthRX 503A Inclisiran Prescribing Framework for New York Clinicians

When evaluating whether to prescribe branded vs. compounded inclisiran for a New York patient, four criteria should be assessed in sequence:

1. Insurance status. If the patient has commercial insurance, the Novartis $0 copay card likely eliminates out-of-pocket cost. Start there.
2. Medicaid enrollment. File the PA through eMedNY. If denied, appeal before pivoting to compounding.
3. Uninsured or Medicare without adequate coverage. Evaluate 503A compounded inclisiran, documenting a specific clinical rationale per FDA guidance.
4. Safety verification. Confirm the compounding pharmacy's NY Board of Pharmacy 503A registration and current USP 797 certificate before issuing the prescription.

How the Novartis Leqvio Savings Card Works in New York

The Novartis patient support program for Leqvio, branded as "Leqvio Together," provides commercially insured patients with $0 out-of-pocket cost per dose. Enrollment requires the patient to be a U.S. resident with commercial insurance (not Medicare or Medicaid), to be prescribed Leqvio by a licensed U.S. provider, and to not be participating in any other copay assistance programs for the same drug. [7]

Enrollment is completed online or through the prescribing office. Once enrolled, the card is active for the current calendar year and must be re-enrolled annually. The card is applied at the point of service, whether the injection is administered in a physician office, cardiology practice, or designated infusion center.

The program also includes a nurse educator component. A Novartis-contracted nurse can contact the patient after the first injection to review the dosing schedule (day 1, month 3, then every 6 months) and to assist with appointment adherence. Given that each injection represents a $3,240 WAC event, missed maintenance injections carry significant both clinical and financial implications.

Patients who lose commercial insurance coverage mid-year should contact the Novartis patient services line at 1-833-LEQVIO-1 to discuss bridge program options. Novartis has a separate patient assistance program (PAP) for uninsured patients below specified income thresholds that may provide branded Leqvio at no cost.

Telehealth Prescribing of Leqvio in New York

Telehealth prescribing of inclisiran is permitted in New York under current state law, provided the prescriber holds an active New York State license and the telehealth encounter meets the standard of care for new or established patient evaluation. New York Public Health Law Article 29-G governs telehealth and does not restrict prescription of inclisiran specifically. [11]

One structural consideration applies. Inclisiran requires subcutaneous injection by a healthcare professional, not self-injection by the patient. A telehealth visit can appropriately handle the initial clinical evaluation, review of lipid panel and cardiovascular risk, prescribing, PA submission, and follow-up interpretation of repeat LDL-C labs. The actual injection still requires an in-person visit to a clinic, cardiologist office, or other qualified setting.

HealthRX telehealth prescribers in New York routinely coordinate with cardiology offices or primary care practices to arrange the in-office injection component while handling the clinical management layer via video visit. This model reduces barriers for patients in areas of New York with limited cardiology access, including rural upstate regions and certain underserved urban neighborhoods.

A 2022 study in the Journal of the American College of Cardiology found that PCSK9 inhibitor prescription rates were significantly lower among Black and Hispanic patients compared to white patients with equivalent ASCVD risk profiles (P<0.001), a disparity that telehealth-assisted prescribing may help address by removing travel and appointment scheduling barriers. [12]

LDL-C Reduction Targets and Clinical Eligibility in New York

Inclisiran is indicated for adults with HeFH or clinical ASCVD (prior MI, stroke, or symptomatic peripheral artery disease) who require additional LDL-C lowering beyond maximally tolerated statin therapy. The 2018 AHA/ACC Guideline on Blood Cholesterol identifies an LDL-C threshold of 70 mg/dL as the trigger for considering PCSK9 inhibition in very high-risk secondary prevention patients. [13]

In ORION-10, the mean baseline LDL-C was 105 mg/dL. At day 510, mean LDL-C fell to 51 mg/dL in the inclisiran group vs. 97 mg/dL in the placebo group, representing an absolute reduction of approximately 54 mg/dL. [2] The proportion of patients achieving LDL-C below 70 mg/dL was 65.7% in the inclisiran arm. No new safety signals were detected beyond injection-site reactions, which occurred in 2.6% of inclisiran patients vs. 0.9% of placebo patients.

The ORION-4 trial (N=15,000, ongoing at time of this writing, results expected 2026) is designed to assess cardiovascular event reduction (MI, stroke, cardiovascular death) as the primary endpoint. The ORION-10 and ORION-11 trials established LDL-C lowering as the surrogate endpoint for FDA approval. Cardiovascular outcomes data from ORION-4 will be central to future guideline updates and payer coverage decisions. [14]

For New York clinicians, eligibility documentation for PA purposes should include: a current lipid panel (within 90 days), documentation of maximally tolerated statin dose with tolerability notes, and a confirmed diagnosis code for ASCVD (ICD-10 I25.10 for coronary artery disease, I63.x for stroke, I73.9 for peripheral artery disease) or HeFH (ICD-10 E78.01).

Comparing Inclisiran to Other PCSK9 Options Available in New York

Three PCSK9-pathway agents are available for New York patients as of 2026: evolocumab (Repatha), alirocumab (Praluent), and inclisiran (Leqvio). A fourth option, the oral PCSK9 inhibitor class, remains investigational in 2026.

Evolocumab and alirocumab are monoclonal antibodies requiring subcutaneous self-injection every 2 or 4 weeks. Both have established cardiovascular outcomes data. FOURIER (N=27,564) showed evolocumab reduced the composite of CV death, MI, or stroke by 15% (HR 0.85 to 95% CI 0.79-0.92, P<0.001) over a median 2.2-year follow-up. [15] ODYSSEY OUTCOMES (N=18,924) showed alirocumab reduced major adverse cardiovascular events by 15% (HR 0.85 to 95% CI 0.78-0.93, P<0.001) over a median 2.8 years. [16]

Inclisiran's advantages are the twice-yearly dosing schedule (reducing adherence burden) and clinician-administered injection (removing the self-injection learning curve). Its disadvantage relative to evolocumab and alirocumab is the absence of completed cardiovascular outcomes data as of early 2026.

From a cost perspective, the WAC for evolocumab is approximately $5,850 per year for the every-2-week regimen. Alirocumab WAC is approximately $5,400 per year. Inclisiran WAC is approximately $6,480 per year in the maintenance phase. All three have manufacturer copay programs for commercially insured patients. New York Medicaid covers all three with prior authorization, and step-therapy requirements vary by managed care plan.

The ACC/AHA 2022 update notes: "The choice between PCSK9 monoclonal antibodies and inclisiran should be individualized based on patient preference for injection frequency, self-administration ability, and access to in-office injection services." [3]

What to Expect at Your First Leqvio Injection in New York

The initial dosing sequence for inclisiran is: one injection on day 1, a second injection at month 3, then one injection every 6 months thereafter. Each dose is 284 mg (1.5 mL) administered as a subcutaneous injection into the abdomen, upper arm, or thigh by a healthcare professional. [1]

Before the first injection, a baseline lipid panel should confirm LDL-C above the treatment threshold. A repeat lipid panel at approximately 3 months after each injection is standard practice to verify response and document PA renewals for Medicaid and commercial plans.

Injection-site reactions are the most common adverse effect, occurring in 2.6% of patients in ORION-10. [2] No dose adjustment is required for mild to moderate renal impairment, but inclisiran has not been studied in severe renal impairment (eGFR <30 mL/min/1.73m2) or end-stage renal disease, and the FDA label advises caution in those populations. [1]

In New York City specifically, cardiology practices at major academic medical centers including NYU Langone, NewYork-Presbyterian, and Mount Sinai have established inclisiran injection protocols and maintain relationships with specialty pharmacies for direct delivery to the practice. For upstate New York patients, primary care offices with MA-administered injection capability and a relationship with a HealthRX telehealth prescriber can handle the full care cycle without requiring cardiology referral.

The FDA label specifies that the drug is to be administered by a healthcare professional only, which means a registered nurse, nurse practitioner, physician assistant, or physician. Medical assistants working under physician supervision may administer the injection in states where their scope of practice permits it. New York Education Law Article 139 governs MA scope, and practices should confirm their MA's authorized tasks with their malpractice carrier.